TOPK Inhibition Enhances the Sensitivity of Colorectal Cancer Cells to Radiotherapy by Reducing the DNA Damage Response

Abstract

Objective

Abnormal expression of T-lymphokine-activated killer cell-originated protein kinase (TOPK) was reported to be closely related to the resistance of prostate cancer to radiotherapy and to targeted drug resistance in lung cancer. However, the role of TOPK inhibition in enhancing radiosensitivity of colorectal cancer (CRC) cells is unclear. This study aimed to evaluate the radiosensitization of TOPK knockdown in CRC cells.

Methods

The expression of TOPK was detected in CRC tissues by immunohistochemistry, and the effect of TOPK knockdown was detected in CRC cells by Western blotting. CCK-8 and clonogenic assays were used to detect the growth and clonogenic ability of CRC cells after TOPK knockdown combined with radiotherapy in CRC cells. Furthermore, proteomic analysis showed that the phosphorylation of TOPK downstream proteins changed after radiotherapy. DNA damage was detected by the comet assay. Changes in the DNA damage response signaling pathway were analyzed by Western blotting, and apoptosis was detected by flow cytometry.

Results

The expression of TOPK was significantly greater in CRC tissues at grades 2–4 than in those at grade 1. After irradiation, CRC cells with genetically silenced TOPK had shorter comet tails and reduced expression levels of DNA damage response-associated proteins, including phospho-cyclin-dependent kinase 1 (p-CDK1), phospho-ataxia telangiectasia-mutated (p-ATM), poly ADP-ribose polymerase (PARP), and meiotic recombination 11 homolog 1 (MRE11).

Conclusions

TOPK was overexpressed in patients with moderately to poorly differentiated CRC. Moreover, TOPK knockdown significantly enhanced the radiosensitivity of CRC cells by reducing the DNA damage response.

References

[1] ChenB, AlaradoDM, IticoviciM, et al.. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer. Cancer Immunol Res, 2020, 8(4): 451-464

[2] SungH, FerlayJ, SiegelRL, et al.. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249

[3] XiY, XuP. Global colorectal cancer burden in 2020 and projections to 2040. Transl Oncol, 2021, 14(10): 101174

[4] ParkSY, LeeCJ, ChoiJH, et al.. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. J Exp Clin Cancer Res, 2019, 38(1): 399

[5] DekkerE, TanisPJ, VleugelsJLA, et al.. Colorectal cancer. Lancet, 2019, 394(10207): 1467-1480

[6] SiegelRL, MillerIKD, JemalA. Cancer statistics, 2019. CA Cancer J Clin, 2019, 69(1): 7-34

[7] GaudetS, BrantonD, LueRA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci U S A, 2000, 97(10): 5167-5172

[8] AbeY, MatsumotoS, KitoK, et al.. Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem, 2000, 275(28): 21525-21531

[9] HerbertKJ, AshtonTM, PrevoR, et al.. T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. Cell Death Dis, 2018, 9(11): 1089

[10] ParkJH, LinML, NishidateT, et al.. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res, 2006, 66(18): 9186-9195

[11] Brown-clayJD, ShenoyDN, TimofeevaO, et al.. PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion. Oncotarget, 2015, 6(17): 15594-15609

[12] OhashiT, KomastuS, IchikawaD, et al.. Overexpression of PBK/TOPK relates to tumor malignant potential and poor outcome of gastric carcinoma. Br J Cancer, 2016, 116(2): 218-226

[13] OhashiT, KomatsuS, IchikawaD, et al.. Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma. Anticancer Res, 2016, 36(12): 6457-6466

[14] QiaoL, BaJ, XieJ, et al.. Overexpression of PBK/TOPK relates to poor prognosis of patients with breast cancer: a retrospective analysis. World J Surg Oncol, 2022, 20(1): 316

[15] Simons-evelynM, Bailey-dellK, ToretskyJA, et al.. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt’s lymphoma and other highly proliferative malignant cells. J Blood Cells Mol Dis, 2001, 27(5): 825-829

[16] ZhuF, ZykovaTA, KangBS, et al.. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells. Gastroenterology, 2007, 133(1): 219-231

[17] ZykovaTA, ZhuF, WangL, et al.. The T-LAK Cell-originated Protein Kinase Signal Pathway Promotes Colorectal Cancer Metastasis. EBioMedicine, 2017, 18: 73-82

[18] LiY, YangZ, LiW, et al.. TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun. Oncotarget, 2016, 7(6): 6748-6764

[19] KruthikaBS, JainR, ArivazhaganA, et al.. Transcriptome profiling reveals PDZ binding kinase as a novel biomarker in peritumoral brain zone of glioblastoma. J Neurooncol, 2018, 141(2): 315-325

[20] MaoP, BaoG, WangYC, et al.. PDZ-Binding Kinase-Dependent Transcriptional Regulation of CCNB2 Promotes Tumorigenesis and Radio-Resistance in Glioblastoma. Transl Oncol, 2020, 13(2): 287-294

[21] MaH, QiG, HanF, et al.. PBK drives PARP inhibitor resistance through the TRIM37/NFkappaB axis in ovarian cancer. Exp Mol Med, 2022, 54(7): 999-1010

[22] ParkJH, ParkSA, LeeYJ, et al.. PBK attenuates paclitaxel-induced autophagic cell death by suppressing p53 in H460 non-small-cell lung cancer cells. FEBS Open Bio, 2020, 10(5): 937-950

[23] XiaoJJ, WangF, LuH, et al.. Targeting the COX2/MET/TOPK signaling axis induces apoptosis in gefitinib-resistant NSCLC cells. Cell Death Dis, 2019, 10(10): 777

[24] PirovanoG, AshtonTM, HerbertKJ, et al.. TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy. Br J Cancer, 2017, 117(4): 503-512

[25] AmeJC, SpenlehauerC, MurciaGD. The PARP superfamily. Bioessays, 2004, 26(8): 882-893

[26] BhartiSK, BroshRM. Fine-tuning DNA repair by protein acetylation. Cell Cycle, 2016, 15(15): 1952-1953

[27] CarneyJP, MaserRS, OlivaresH, et al.. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell, 1998, 93(3): 477-486

[28] HabrakenY, JoloisO, PietteJ. Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray. Oncogene, 2003, 22(38): 6090-6099

[29] KobayashiJ. Molecular mechanism of the recruitment of NBS1/hMRE11/hRAD50 complex to DNA double-strand breaks: NBS1 binds to gamma-H2AXthrough FHA/BRCT domain. J Radiat Res, 2004, 45(4): 473-47

[30] AbrahamRT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes & Dev, 2001, 15(17): 2177-2196

[31] KhosraviR, MayaR, GottliebT, et al.. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc Natl Acad Sci U S A, 1999, 96(26): 14973-14977

[32] WangXJ, ChuHY, LvMJ, et al.. Structure of the intact ATM/ Tel1 kinase. Nature Communications, 2016, 7: 11655

[33] JinMH, OhDY. ATM in DNA repair in cancer. Pharmacol Ther, 2019, 203: 107391

[34] WangYQ, YangLF, ZhangJ, et al.. Radiosensitization by irinotecan is attributed to G2/M phase arrest, followed by enhanced apoptosis, probably through the ATM/Chk/Cdc25C/Cdc2 pathway in p53-mutant colorectal cancer cells. Int J Oncol, 2018, 53(4): 1667-1680

[35] Wang Z, Lai ST, Ma NY, et al. Radiosensitization of metformin in pancreatic cancer cells via abrogating the G2 checkpoint and inhibiting DNA damage repair. Cancer Lett, 369(1):192–201

[36] MatsuoY, ParkJH, MiyamotoT, et al.. TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis. Sci Transl Med, 2014, 6(259): 259ra145

[37] HerbertKJ, PuliyadiR, PrevoR, et al.. Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress. Cell Death Differ, 2021, 28(4): 1333-1346

[38] Mirza-aghazadeh-attariM, DarbandSG, KavianiM, et al.. DNA damage response and repair in colorectal cancer: Defects, regulation and therapeutic implications. DNA Repair (Amst), 2018, 69: 34-52

[39] HuangRX, ZhouPK. DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer. Signal Transduct Target Ther, 2020, 5(1): 60

[40] DengS, VlatkovicT, LiMY, et al.. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers (Basel), 2022, 14(19): 4874